26 min listen
Black patients with ES-SCLC get less chemo, CTCs may guide breast cancer treatment, and new FDA approvals for neuroblastoma and prostate cancer
FromBlood & Cancer
Black patients with ES-SCLC get less chemo, CTCs may guide breast cancer treatment, and new FDA approvals for neuroblastoma and prostate cancer
FromBlood & Cancer
ratings:
Length:
9 minutes
Released:
Dec 8, 2020
Format:
Podcast episode
Description
Blood & Cancer news stories: Black patients with ES-SCLC get less chemo but have better survival: https://bit.ly/33Rb5eB Should CTCs guide treatment choice in HR+, HER2– breast cancer?: https://bit.ly/3gn6shc New drug approved for relapsed/refractory neuroblastoma: https://bit.ly/2VMpvIy FDA approves first agent for PSMA-PET imaging in prostate cancer: https://bit.ly/36TAaY7 Contact Blood & Cancer at podcasts@mdedge.com.
Released:
Dec 8, 2020
Format:
Podcast episode
Titles in the series (100)
Sickle cell update: Treating pain and progress toward cure: When it comes to treating pain related to sickle cell disease, consider the underlying factors, from constipation to compression spine deformity. That’s just some of the advice from Ifeyinwa Osunkwo, MD, of Atrium Health and Levine Cancer Institute... by Blood & Cancer